GH Research PLC (GHRS): Price and Financial Metrics

GH Research PLC (GHRS): $9.53

0.28 (+3.03%)

POWR Rating

Component Grades













Add GHRS to Watchlist
Sign Up

Industry: Biotech



in industry

GHRS Stock Price Chart Interactive Chart >

Price chart for GHRS

GHRS Price/Volume Stats

Current price $9.53 52-week high $20.34
Prev. close $9.25 52-week low $8.46
Day low $9.33 Volume 3,865
Day high $9.70 Avg. volume 23,978
50-day MA $10.25 Dividend yield N/A
200-day MA $11.66 Market Cap 481.47M

GH Research PLC (GHRS) Company Bio

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.

GHRS Latest News Stream

Event/Time News Detail
Loading, please wait...

GHRS Latest Social Stream

Loading social stream, please wait...

View Full GHRS Social Stream

Latest GHRS News From Around the Web

Below are the latest news stories about GH RESEARCH PLC that investors may wish to consider to help them evaluate GHRS as an investment opportunity.

7 Short-Squeeze Stocks for Bold Contrarians to Consider

While market volatility has brough the bears out of hibernation, certain short-squeeze stocks could be a trap for the pessimists.

Josh Enomoto on InvestorPlace | November 21, 2022

JMP Securities Sticks to Their Buy Rating for GH Research (GHRS)

E ratio of -44.86.

Ryan Adist on TipRanks | November 10, 2022

GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2022 and gave updates on its business. Third Quarter 2022 Financial Highlights Cash position Cash was $256.9 million as of September 30, 2022, compared to $276.8 million as of December 31, 2021. We believe that our e

Yahoo | November 10, 2022

4 Out Of 5 Cannabis Category Indexes Improved Last Week

All four of our cannabis-related indexes were up last week, while only the partly-related Psychedelic Compounds index dropped again. | October 24, 2022

Wall Street Analysts See a 262% Upside in GH Research PLC (GHRS): Can the Stock Really Move This High?

The consensus price target hints at a 262% upside potential for GH Research PLC (GHRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | September 14, 2022

Read More 'GHRS' Stories Here

GHRS Price Returns

1-mo 0.74%
3-mo -10.09%
6-mo -14.61%
1-year -40.59%
3-year N/A
5-year N/A
YTD -1.95%
2022 -58.34%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.719 seconds.